Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Loa Loa (eye worm) | carbonic anhydrase 3 | 0.0096 | 0.3896 | 0.4864 |
Echinococcus multilocularis | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Trypanosoma brucei | RNA helicase, putative | 0.0125 | 0.7039 | 1 |
Schistosoma mansoni | carbonic anhydrase | 0.0096 | 0.3896 | 0.3896 |
Loa Loa (eye worm) | protein-tyrosine phosphatase | 0.0134 | 0.801 | 1 |
Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Echinococcus multilocularis | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0096 | 0.3896 | 0.5 |
Schistosoma mansoni | carbonic anhydrase-related | 0.0096 | 0.3896 | 0.3896 |
Echinococcus granulosus | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Echinococcus multilocularis | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Plasmodium vivax | plasmepsin V, putative | 0.0139 | 0.8517 | 1 |
Plasmodium falciparum | carbonic anhydrase | 0.0096 | 0.3896 | 0.4574 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0153 | 1 | 1 |
Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.0096 | 0.3896 | 0.3896 |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.0134 | 0.801 | 1 |
Schistosoma mansoni | protein tyrosine phosphatase n11 (shp2) | 0.0134 | 0.801 | 0.801 |
Plasmodium falciparum | plasmepsin V | 0.0139 | 0.8517 | 1 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.0134 | 0.801 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0096 | 0.3896 | 0.6397 |
Echinococcus multilocularis | carbonic anhydrase II | 0.0096 | 0.3896 | 0.4864 |
Brugia malayi | Protein-tyrosine phosphatase containing protein | 0.0134 | 0.801 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0096 | 0.3896 | 0.4864 |
Toxoplasma gondii | aspartyl protease ASP5 | 0.0116 | 0.609 | 1 |
Leishmania major | carbonic anhydrase-like protein | 0.0096 | 0.3896 | 0.5 |
Echinococcus granulosus | carbonic anhydrase II | 0.0096 | 0.3896 | 0.4864 |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.0134 | 0.801 | 1 |
Echinococcus granulosus | carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.0096 | 0.3896 | 0.4864 |
Schistosoma mansoni | carbonic anhydrase-related | 0.0096 | 0.3896 | 0.3896 |
Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.0096 | 0.3896 | 0.3896 |
Schistosoma mansoni | hypothetical protein | 0.0125 | 0.7039 | 0.7039 |
Schistosoma mansoni | carbonic anhydrase-related | 0.0096 | 0.3896 | 0.3896 |
Schistosoma mansoni | hypothetical protein | 0.0096 | 0.3896 | 0.3896 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0059 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0096 | 0.3896 | 0.4864 |
Loa Loa (eye worm) | hypothetical protein | 0.0096 | 0.3896 | 0.4864 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.0134 | 0.801 | 1 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.0096 | 0.3896 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 20 uM | Inhibition of Human immunodeficiency virus 1 integrase 3'-processing activity after 30 mins by polyacrylamide gel electrophoresis | ChEMBL. | 24084160 |
IC50 (binding) | = 20 uM | Inhibition of Human immunodeficiency virus 1 integrase strand transfer activity after 30 mins by polyacrylamide gel electrophoresis | ChEMBL. | 24084160 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.